EN
* Advanced precancerous lesions including advanced adenoma (tubular adenoma measuring ≥ 1 cm in greatest diameter, or adenoma with significant villous features), large serrated lesions or high-grade dysplasia.
Sample collection process is designed with privacy and convenience in mind. Customers can collect stool samples in the comfort of their homes and mail samples back to the processing laboratories.
Non-invasive and painless test uses stool samples to perform early detection of colorectal cancer and does not require bowel preparation.
The multi-biomarker DNA and FIT combined testing technology increases rate of detection of colorectal cancer and pre-cancerous lesions, offering ideal performance for colorectal cancer early screening.
BGI can provide entire end-to-end testing infrastructure.
Stories are from actual patients (with alias names). Written consent to share was obtained from them.
Catherine considers herself to have good gut health and never feels any discomfort. Her father was diagnosed with colorectal cancer, which worries her because she understands that people with a family history of colorectal cancer are at increased risk.*
Catherine took the COLOTECT test, and the test result was positive. She visited a doctor and underwent a colonoscopy. A total of 11 adenomas were found and diagnosed as cancerous.
The adenomas were removed and pathology confirmed as stage IA colorectal cancer. Catherine is now recovered and discharged from the hospital. Because of the positive family history, Catherine’s brother also took the COLOTECT test. The test result came back positive. He went for a follow-up colonoscopy; polyps were found and removed.
Whitney has had normal results from her routine health check-ups in the last two years, which includes fecal immunochemical tests (FIT) for colorectal cancer. She does not feel any discomfort.
Whitney pays close attention to her gastrointestinal health because her father was diagnosed with gastric cancer. She took the COLOTECT test, and the test result was positive. She was then scheduled for a combined gastroscopy and colonoscopy.
Whitney was found to have inflammation and polyps in her stomach and a 2.5cm polyp in her sigmoid colon, which was removed and later pathologically diagnosed as tubulovillous adenoma.
George visited a doctor because of gut problems and discomfort. He did a fecal immunochemical test (FIT), and the test result was normal.
George has an unhealthy diet, and his sister previously had colon polyps. His daughter then recommended COLOTECT to him. He took the COLOTECT test, and the test result came back positive.
George underwent a colonoscopy, and a 0.4cm rectal polyp was identified. The polyp was removed promptly to avoid further progression.
Yannis has an unhealthy diet. He has occasional constipation and blood in the stool. Considering his health condition and his father’s history of intestinal disease, Yannis took the COLOTECT test, and the result came back positive.
Yannis underwent a gastroscopy and colonoscopy, which showed that he had tubular adenomas and hyperplastic polyps in his colon, hemorrhoid, and polyps in the stomach. He was also diagnosed with gastritis. Yannis had all these conditions treated promptly to avoid progression.
Data protection is important in health-related data. And BGI checks for our data security through independent committees.
Your test results will only be sent to you or your attending physician if requested.
The Combined Detection Kit for Human Gene Methylation and Fecal Occult Blood is a non-invasive in vitro diagnostic (IVD) assay for qualitative detection of certain genes’ methylation and fecal hemoglobin from human stool specimens. The kit is intended to be used for screening colorectal cancer in the general population. A positive test result indicates that the subject may have colorectal cancer and/or advanced adenoma, and further colonoscopy is required; on the contrary, a negative test result indicates that the subject has a low possibility of colorectal cancer and/or advanced adenoma, however, the risk of disease cannot be completely ruled out. The product is applicable to all people between the ages of 40 to 75 who need colorectal cancer screening.
This product cannot replace colonoscopy, and the test results of this kit should not be used as the only basis for clinical diagnosis. Clinicians should comprehensively judge the results based on the patient's condition and other laboratory indicators. CE marked.